MultiHance Side Effects

Severe Side Effects of MultiHance

• MultiHance may cause acute kidney failure in some patients.  
• Cardiac Arrythmia has been reported by some patients who received MultiHance.  This may be potentially fatal depending on the circumstance.  Multihance may cause first degree atrioventricular block which may lead to heart failure.
• MultiHance may cause severe anaphylactic shock or other allergic reactions.  It may also cause an allergic reaction at the injection site as well as possible necrosis around the surrounding area.

Common Side Effects of MultiHance

• The most common side effects reported include upset stomach and vomiting, loose stools, burning around the injection site, headache, and dizzy spells.
• Other side effects include sneezing, stuff nose, rash, swelling, elevated basophil levels in blood, and numbness or tingling in the skin.

Warnings & Recalls for MultiHance

Black Box Warning for MultiHance

• Gadolinium-based contrast agents such as MultiHance may cause Nephrogenic Systemic Fibrosis in patients with compromised kidney function or impaired drug elimination.  This illness is potentially fatal and can affect the skin, eyes, internal organs, and/or joints.  The patient should be tested for kidney problems prior to receiving MultiHance.  

Other Warnings for MultiHance

• MultiHance is a pregnancy category class C drug and may be harmful to take while pregnant.  The drug may cause fetal malformations and/or fetal death.
• Patients with kidney problems should be screened prior to receiving MultiHance.
• Tell your doctor if you are taking medications for cancer including anthracycline and , vinca alkaloid drugs before receiving MultiHance.
• Some patients may be hypersensitive to MulitHance.

MultiHance Treatment and Use

MultiHance| Gadobenate Dimeglumine is a gadolinium-based contrast agent.  It is designed to work with an MRI machine to help clearly visualize lesions and/or abnormal tissue in the brain and spine.  It is also used to diagnose certain kinds of vascular disease in some patients.  Recently, gadolinium-based contrast agents such as MultiHance and Gadoteridol were issued a black box warning due to Nephrogenic Systemic Fibrosis.  MultiHance is marketed by Bracco Diagnostics.

What does MultiHance do?

When used with a Magnetic Resonance Imaging machine, MultiHance helps to create a magnetic moment which helps visualize the targeted area.

Dosage

The usual dose for MultiHance is 0.2 mL per kg of body weight intravenously administered for the Central Nervous System.  For renal and aorto-ilio-femoral vessels, the usual dose is 0.1 mL per kg of body weight.  Following administration of MultiHance, a minimum of 5 mL of saline flush should be injected into the patient for CNS and 20 mL for renal and aorto-ilio-femoral vessels.  MultiHance is available as 529 mg per mL single dose vials and various multi-packs.

Other Names for MultiHance

Brand Name

• MultiHance

Generic Name

•   Gadobenate Dimeglumine

Lawsuits & Legal Information for MultiHance